MindMaze Therapeutics Secures CHF 4 Million Investment
On November 17, 2026,
MindMaze Therapeutics (SIX: MMTX), recognized as a pioneer in scalable precision neurotherapeutics, announced a significant milestone in its growth journey by securing investment commitments totaling up to
CHF 4 million from strategic investors. This financing is set to enhance the commercial deployment of its advanced neurotherapeutics solutions, which are recognized for their clinical validation and applicability in various patient rehabilitation scenarios.
MindMaze has made notable strides in creating and validating solutions that enhance patient recovery trajectories, particularly for conditions such as stroke and Parkinson’s disease. The funds will notably assist in broadening the company's market reach and accelerating revenue growth, as it looks to attract more healthcare providers and facilitate access to home-based rehabilitation solutions through its latest product,
MindMotion Lite. This innovative tablet-based application is specifically designed for home deployment, ensuring that rehabilitation can seamlessly extend beyond clinical settings.
CEO Zach Henderson expressed gratitude towards the investors, stating, "We appreciate our investors' confidence in our ability to scale and their support through their investment and networks. This funding allows us to build on our existing deployments and continue bringing precision neurotherapeutics to more patients." This remark underscores the company's commitment to enhancing patient welfare through innovative technology and financial support.
The investment agreement outlines CHF 3 million in funding that is expected to be received in installments during November and December of 2026, contingent on standard closing conditions. Additionally, there exists an option for an extra
CHF 1 million investment, which can be exercised until February 28, 2027. The financing will occur mainly through the issuance of shares and mandatory convertible notes priced at CHF 0.12 per share. Furthermore, the deal includes
7 million five-year warrants priced at
CHF 0.25 per share, representing a 79% premium compared to the previous day's closing price. An additional 2.5 million warrants will be issued under the same terms if the option is exercised.
In alignment with this strategic maneuver, MindMaze also made a pivotal decision to terminate an
unfunded commitment of CHF 4 million that was previously announced in May 2026. This move signifies the company's dynamic approach towards financing that aligns with its broader goals and immediate needs.
About MindMaze Therapeutics
MindMaze Therapeutics is at the forefront of redefining recovery pathways for patients globally. Utilizing advanced software, proprietary sensors, and AI-supported data analytics, the company offers a coordinated continuum of care from acute hospital settings to outpatient treatment and home therapy. The FDA-listed and CE-marked products aim to address the pressing shortage of specialized clinicians in neurorehabilitation, providing scalable and reimbursable solutions. With a robust library of clinical validation, MindMaze Therapeutics is pioneering the future of neurorestorative medicine.
For additional information, you can visit
MindMaze Therapeutics.
For press inquiries, please contact:
Jeremy Meinen, Chief Financial Officer
[Email: protected]
This announcement includes forward-looking statements based on current plans and assumptions, reflecting significant risks and uncertainties that may affect actual outcomes.